Shire obtained FDA approval to market Vyvanse, or lisdexamfetamine dimesylate, as maintenance therapy for children and teenagers with attention-deficit/hyperactivity disorder. This makes Vyvanse the only stimulant approved for use as a maintenance therapy in all ADHD patients older than 6, Shire says. The approval was based on data from a 32-week trial that showed lower treatment-failure rate among those who received Vyvanse.

Related Summaries